Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)

Delayed Quote. Delayed  - 03/28 05:18:28 pm
13.72 EUR   +0.15%
03/22 PCAS : 2016 Annual Results
02/21 PCAS : 2016 Annual Results
01/31 PCAS : Net Sales as at December 31, 2016
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

PCAS : Extension of the manufacturing between VLG Chem and Sanofi

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/29/2011 | 11:11am CEST
Extension of the manufacturing contract between VLG Chem and  Sanofi until 2015 The PCAS Group and the Sanofi Group have signed an agreement on the extension of the manufacturing contract related to VLG Chem, a 100% PCAS subsidiary, until 2015. About PCAS PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.
Longjumeau, december 27th, 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
03/22 PCAS : 2016 Annual Results
02/21 PCAS : 2016 Annual Results
01/31 PCAS : Net Sales as at December 31, 2016
2016 PCAS : Acquisition of a leading R&D Center
2016 PCAS : Acquisition of a leading r&d center
2016 PCAS : at China INTER LUBRIC 2016
2016 PCAS : net sales as of 30 September, 2016
2016 PCAS : ex-dividend day for interim dividend
2016 PCAS : 1st half 2016 earnings report continued organic growth
2016PCAS : half-yearly earnings release
More news
Sector news : Pharmaceuticals - NEC
08:48aDJDuPont, Dow Get EU Approval for Merger -- WSJ
03/27DJALEXION PHARMACEUTICALS : Names New CEO Following Internal Sales-Practice Probe
03/27DJEU Clears Dow-DuPont Deal With Conditions -- 2nd Update
03/27DJEU Clears Dow-DuPont Deal With Conditions -- Update
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
More sector news : Pharmaceuticals - NEC
Advertisement
Financials (€)
Sales 2017 207 M
EBIT 2017 19,0 M
Net income 2017 11,4 M
Debt 2017 46,1 M
Yield 2017 1,61%
P/E ratio 2017 16,51
P/E ratio 2018 13,61
EV / Sales 2017 1,23x
EV / Sales 2018 1,14x
Capitalization 207 M
More Financials
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Full-screen chart
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 13,9 €
Spread / Average Target 1,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Chief Operating Officer
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Director-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PCAS-2.28%225
JOHNSON & JOHNSON8.91%341 030
ROCHE HOLDING LTD.8.73%220 248
PFIZER INC.5.23%203 546
NOVARTIS AG-0.47%195 735
MERCK & CO., INC.7.34%173 493
More Results